SCHEMBL26313837

SCHEMBL26313837

CCCOC1CC1(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645131 0.86 ADRB2 (0.39)
SCHEMBL19945295 0.79
SCHEMBL21328982 0.77
SCHEMBL22602119 0.75
SCHEMBL22587992 0.75
SCHEMBL21340349 0.75 GRM2 (0.44)
SCHEMBL20780113 0.73 APLNR (0.32)
SCHEMBL23793191 0.73 EPHX2 (0.32)
SCHEMBL10705341 0.69 SMN1; SMN2 (0.31)
SCHEMBL5986833 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225119-A1 STABILIZATION OF INTEGRIN INHIBITORS PLIANT THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 US disclosed
WO-2023077046-A1 INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2023-05-04 WO disclosed